Cladribine in myasthenia gravis: a pilot open-label study

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Myasthenia Gravis (MG) is a rare autoimmune disorder affecting neuromuscular junctions.
• Refractory MG cases present significant treatment challenges.
• Exploring novel therapeutic agents is crucial for managing severe MG.

Purpose of the Study:

• To evaluate the efficacy and safety of cladribine in patients with refractory myasthenia gravis.
• To assess the impact of cladribine on clinical scores and concomitant medication use.

Main Methods:

• Prospective, open-label study design.
• 13 patients with refractory MG received cladribine.
• Clinical response guided repetitive cladribine cycles and steroid dosage.

Main Results:

• 11 out of 13 patients (85%) achieved significant clinical improvement.
• Mean Myasthenia Gravis Composite (MGC) score decreased from 15.1 to 6.3 within 4 months.
• Prednisolone dosage reduced from 9.5 mg to 1.9 mg; no IVIg or PLEX needed; no adverse events reported.

Conclusions:

• Cladribine demonstrates safety and efficacy as an emergency therapy for refractory MG.
• This treatment offers a promising alternative for severe, treatment-resistant myasthenia gravis cases.
• Further research may establish cladribine's role in long-term MG management.